Conclusions:
This is the largest study to investigate the distinct genomic landscape between KMT2-MT and WT GC to date. Our data indicates that GC patients with KMT2 mutations could potentially benefit from agents targeting DNA damage repair and immunotherapy. Efficiency of these therapeutic targets in KMT2-MT GC warrant further in vitro and in vivo investigation.